Surmodics' Q3 Revenue Up, Net Loss Widens Amid R&D Push

TL;DR

Surmodics is burning cash on R&D, widening losses despite revenue growth, making it a risky bet until the GTCR merger clarifies its future.

AI Summary

SURMODICS INC reported a significant increase in revenue for the nine months ended June 30, 2025, with total revenue reaching $80.2 million, up from $72.3 million in the prior year, primarily driven by product sales. The company's net income, however, saw a substantial decline, with a net loss of $10.5 million for the nine months ended June 30, 2025, compared to a net loss of $1.2 million in the same period last year, largely due to increased operating expenses. Key business changes include continued investment in research and development, with expenses rising to $47.3 million for the nine months ended June 30, 2025, from $44.8 million in the prior year, reflecting ongoing product development, particularly in the Medical Device segment. A significant risk highlighted is the potential impact of the GTCR Merger Agreement, announced on May 28, 2024, which could introduce uncertainties regarding future operations and financial performance. The strategic outlook focuses on advancing its Medical Device and In Vitro Diagnostics segments, with product revenue for the Medical Device segment at $40.1 million for the three months ended June 30, 2025, and In Vitro Diagnostics at $10.2 million for the same period. The company also noted a secured term loan facility with Midcap Credit Agreement, initiated on October 13, 2022, impacting its financial structure.

Why It Matters

For investors, the widening net loss despite revenue growth signals potential profitability challenges, especially with increased R&D spending. Employees might face uncertainty given the pending GTCR Merger Agreement, which could lead to operational restructuring. Customers could benefit from the continued investment in product development, potentially leading to innovative medical devices and diagnostics. The broader market for medical technology will watch how Surmodics navigates its strategic investments and the integration of the GTCR merger, as it could set a precedent for similar mid-cap medical device companies in a competitive landscape dominated by larger players like Abbott.

Risk Assessment

Risk Level: high — The risk level is high due to a significant net loss of $10.5 million for the nine months ended June 30, 2025, compared to a $1.2 million net loss in the prior year, indicating deteriorating profitability. Additionally, the pending GTCR Merger Agreement, announced on May 28, 2024, introduces substantial uncertainty regarding the company's future operations and financial structure.

Analyst Insight

Investors should exercise caution and closely monitor the progress and terms of the GTCR Merger Agreement, as it will be a pivotal factor in Surmodics' future valuation. Consider holding off on new investments until more clarity emerges regarding the merger's impact on profitability and strategic direction, especially given the widening net losses.

Financial Highlights

revenue

$80.2M

net Income

-$10.5M

revenue Growth

+11.0%

Revenue Breakdown

Key Numbers

• $80.2M — Total Revenue (for the nine months ended June 30, 2025, up from $72.3 million in the prior year)
• $10.5M — Net Loss (for the nine months ended June 30, 2025, compared to a $1.2 million net loss in the prior year)
• $47.3M — Research and Development Expenses (for the nine months ended June 30, 2025, up from $44.8 million in the prior year)
• $40.1M — Medical Device Segment Product Revenue (for the three months ended June 30, 2025)
• $10.2M — In Vitro Diagnostics Segment Product Revenue (for the three months ended June 30, 2025)

Key Players & Entities

• SURMODICS INC (company) — filer of the 10-Q
• GTCR Merger Agreement (company) — significant corporate event announced on May 28, 2024
• Midcap Credit Agreement (company) — provider of secured term loan facilities initiated on October 13, 2022
• Abbott (company) — partner in a significant agreement
• Embolitech LLC (company) — entity related to in-process research and development

FAQ

Risk Factors

• GTCR Merger Agreement Uncertainty [high — financial]: The announcement of the GTCR Merger Agreement on May 28, 2024, introduces potential uncertainties regarding Surmodics' future operations and financial performance. Investors should monitor how this agreement impacts strategic decisions and market perception.
• Increased R&D Investment [medium — operational]: Research and development expenses rose to $47.3 million for the nine months ended June 30, 2025, from $44.8 million in the prior year. While this reflects ongoing product development, it contributes to the current net loss and requires careful management to ensure future returns.
• Significant Net Loss [high — financial]: The company reported a net loss of $10.5 million for the nine months ended June 30, 2025, a substantial increase from the $1.2 million net loss in the same period last year. This widening loss, driven by increased operating expenses, is a key concern for profitability.
• Debt Financing [medium — financial]: The company has a secured term loan facility with Midcap Credit Agreement, initiated on October 13, 2022. This debt impacts the company's financial structure and introduces interest payment obligations.

Industry Context

Surmodics operates in the medical technology sector, specifically focusing on device coatings and in vitro diagnostics. This industry is characterized by high R&D investment, stringent regulatory requirements, and a competitive landscape driven by innovation and strategic partnerships. Companies often rely on intellectual property and technological advancements to maintain market share.

Regulatory Implications

As a medical technology company, Surmodics is subject to rigorous regulatory oversight from bodies like the FDA. Changes in regulations, compliance costs, and the approval process for new products can significantly impact operations and market access. The company's investments in R&D are geared towards navigating these regulatory pathways.

What Investors Should Do

1. Monitor the impact of the GTCR Merger Agreement.
2. Analyze the drivers of increased operating expenses and net loss.
3. Evaluate the progress and return on R&D investments.
4. Assess the company's debt structure and repayment capacity.

Key Dates

• 2024-05-28: Announcement of GTCR Merger Agreement — Introduces potential uncertainty regarding future operations and financial performance.
• 2022-10-13: Initiation of Midcap Credit Agreement (Secured Term Loan Facility) — Impacts the company's financial structure and introduces debt obligations.
• 2025-06-30: End of Nine-Month Period for Reporting — Key period for evaluating revenue growth and net loss trends.

Glossary

GTCR Merger Agreement

An agreement for a merger or acquisition involving GTCR, a private equity firm. Such agreements can create significant changes in a company's ownership, strategy, and operations. (A major event creating uncertainty and potential future changes for Surmodics.)

Medical Device Segment

A business segment focused on products used in medical procedures and devices. Surmodics is investing heavily in this area. (A key growth driver for Surmodics, with significant product revenue reported.)

In Vitro Diagnostics Segment

A business segment focused on tests performed on samples such as blood or tissue outside the body. This is another strategic focus for Surmodics. (Represents a growing area of Surmodics' business, contributing to overall product revenue.)

Secured Term Loan Facility

A type of loan that is backed by specific collateral. This facility provides the company with borrowed funds but also creates a debt obligation. (Indicates a source of financing that impacts Surmodics' balance sheet and financial obligations.)

Year-Over-Year Comparison

Total revenue for the nine months ended June 30, 2025, increased by 11.0% to $80.2 million compared to $72.3 million in the prior year, primarily driven by product sales. However, this revenue growth was overshadowed by a significant increase in operating expenses, leading to a net loss of $10.5 million, a substantial deterioration from the $1.2 million net loss reported in the same period last year. New risks, such as the potential impact of the GTCR Merger Agreement announced in May 2024, have emerged, adding a layer of uncertainty not present in prior filings.

Key Financial Figures

• $0.05 — nge on which registered Common Stock, $0.05 par value SRDX Nasdaq Global Select

Filing Documents

• srdx-20250630.htm (10-Q) — 2625KB
• srdx-ex31_1.htm (EX-31.1) — 17KB
• srdx-ex31_2.htm (EX-31.2) — 17KB
• srdx-ex32_1.htm (EX-32.1) — 10KB
• srdx-ex32_2.htm (EX-32.2) — 11KB
• 0000950170-25-105477.txt ( ) — 9969KB
• srdx-20250630.xsd (EX-101.SCH) — 1129KB
• srdx-20250630_htm.xml (XML) — 2048KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Unaudited Condensed Consolidated Financial Statements 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 33 Item 4.

Controls and Procedures

Controls and Procedures 33

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 34 Item 1A.

Risk Factors

Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35 Item 3. Defaults Upon Senior Securities 35 Item 4. Mine Safety Disclosures 35 Item 5. Other Information 35 Item 6. Exhibits 36

SIGNATURES

SIGNATURES 37 2 Table of Contents

FINANC IAL INFORMATION

PART I. FINANC IAL INFORMATION

Unaudited Condensed Consolidated Financial Statements

Item 1. Unaudited Condensed Consolidated Financial Statements Surmodics, Inc. and Subsidiaries Condensed Consolidated Balance Sheets June 30, September 30, 2025 2024 (In thousands, except per share data) (Unaudited) ASSETS Current Assets: Cash and cash equivalents $ 26,281 $ 36,115 Available-for-sale securities 6,447 3,997 Accounts receivable, net of allowances of $ 143 and $ 144 as of June 30, 2025 and September 30, 2024, respectively 13,169 13,292 Contract assets 9,338 9,872 Inventories 15,756 15,168 Income tax receivable 702 — Prepaids and other 4,301 2,860 Total Current Assets 75,994 81,304 Property and equipment, net 22,840 24,956 Intangible assets, net 21,621 23,569 Goodwill 46,317 44,640 Other assets 3,050 4,093 Total Assets $ 169,822 $ 178,562 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 5,928 $ 2,786 Accrued liabilities: Compensation 7,434 11,099 Accrued other 5,233 3,795 Deferred revenue 846 1,619 Income tax payable — 1,244 Total Current Liabilities 19,441 20,543 Long-term debt, net 29,666 29,554 Deferred income taxes 1,744 1,785 Other long-term liabilities 7,662 7,783 Total Liabilities 58,513 59,665 Commitments and Contingencies (Note 11) Stockholders' Equity: Series A Preferred stock — $ .05 par value, 450 shares authorized; no shares issued and outstanding — — Common stock — $ .05 par value, 45,000 shares authorized; 14,298 and 14,325 shares issued and outstanding as of June 30, 2025 and September 30, 2024, respectively 715 716 Additional paid-in capital 47,861 44,594 Accumulated other comprehensive income (loss) 1,198 ( 2,126 ) Retained earnings 61,535 75,713 Total Stockholders' Equity 111,309 118,897 Total Liabilities and Stockholders' Equity $ 169,822 $ 178,562 The accompanying notes are an in

View Full Filing

View this 10-Q filing on SEC EDGAR